Document is current
Any future updates will be listed below
-
Authors
Yu, Fei
Wang, Rui
Wang, Keli
Lin, BoYang
Zhou, Xuan
Chen, Linghong
Ma, Li
Liao, Zheng
Zhang, Wanggang
-
Funding
Funding for this research was provided by:
Jiangsu Nhwa Pharmaceutical Co., Ltd
- License Information
-
More Information
Article History
Received: 23 December 2024
Accepted: 23 April 2025
First Online: 15 May 2025
Declarations
:
: The trial received ethical approval from the Ethics Committee of Zhejiang Hospital, bearing the approval number 2023 Clinical Review (02G). The study was independently conducted at the Phase I Clinical Trial Research Center of Zhejiang Hospital, spanning from April 13, 2023, to May 23, 2023. The research adhered strictly to the standards set by the Declaration of Helsinki, the Guidelines of Good Clinical Practice, and all other pertinent guiding principles. All participants involved in the trial provided informed consent.
: Not applicable.
: The authors declare no competing interests.
